Aligos Therapeutics

ALGS · NASDAQ

$5.03+$0.19 (+3.93%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $4.84

About ALGS

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 82 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Employees: 82
Headquarters: South San Francisco, California
Listed: Oct 16, 2020
Sector: Health Care
Industry: Biotechnology
Website: aligos.com

Leadership

Aligos Therapeutics executives
Name	Title	Since	Age
Lawrence Blatt	—	2018	63
Lesley Calhoun	—	—	59
Julian Symons	—	—	64
James Hassard	—	—	58
Margarita Chavez	—	—	55
K. Peter Hirth	—	—	73
Bridget Martell	—	—	59
Carole Nuechterlein	—	—	64
Heather Preston	—	—	59
James Scopa	—	—	66
Jordyn Tarazi	—	2024	—

Similar companies

Companies in the same industry as Aligos Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.